Ceftazidime

"Ceftazidime" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients.

Descriptor ID	D002442
MeSH Number(s)	D02.065.589.099.249.210.150 D02.886.665.074.210.150 D03.633.100.300.249.210.150
Concept/Terms	Ceftazidime Ceftazidime Ceftazidime Pentahydrate Pentahydrate, Ceftazidime Fortum Fortum Ceftazidime Anhydrous Ceftazidime Anhydrous Anhydrous, Ceftazidime LY-139381 LY-139381 LY 139381 LY139381 Tazidime Tazidime Fortaz Fortaz GR-20263 GR-20263 GR 20263 GR20263

Below are MeSH descriptors whose meaning is more general than "Ceftazidime".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Amides [D02.065]
Lactams [D02.065.589]
beta-Lactams [D02.065.589.099]
Cephalosporins [D02.065.589.099.249]
Cephaloridine [D02.065.589.099.249.210]
Ceftazidime [D02.065.589.099.249.210.150]
Sulfur Compounds [D02.886]
Thiazines [D02.886.665]
Cephalosporins [D02.886.665.074]
Cephaloridine [D02.886.665.074.210]
Ceftazidime [D02.886.665.074.210.150]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, Fused-Ring [D03.633]
Heterocyclic Compounds, 2-Ring [D03.633.100]
beta-Lactams [D03.633.100.300]
Cephalosporins [D03.633.100.300.249]
Cephaloridine [D03.633.100.300.249.210]
Ceftazidime [D03.633.100.300.249.210.150]

Below are MeSH descriptors whose meaning is related to "Ceftazidime".

Below are MeSH descriptors whose meaning is more specific than "Ceftazidime".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Ceftazidime" by people in this website by year, and whether "Ceftazidime" was a major or minor topic of these publications.

Bar chart showing 31 publications over 15 distinct years, with a maximum of 6 publications in 2018

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2003	0	1	1
2005	0	1	1
2006	0	1	1
2009	0	1	1
2010	0	1	1
2011	0	1	1
2013	1	1	2
2014	0	2	2
2015	0	1	1
2016	4	1	5
2018	4	2	6
2019	1	2	3
2021	1	0	1
2022	1	2	3
2023	0	2	2

Below are the most recent publications written about "Ceftazidime" by people in Profiles.

Wise MG, Karlowsky JA, Mohamed N, Kamat S, Sahm DF. In vitro activity of aztreonam-avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019-2021. Eur J Clin Microbiol Infect Dis. 2023 Sep; 42(9):1135-1143.

View in: PubMed
Karlowsky JA, Hackel MA, Stone GG, Sahm DF. In Vitro Activity of Ceftibuten-Avibactam against ?-Lactamase-Positive Enterobacterales from the ATLAS Global Surveillance Program. Antimicrob Agents Chemother. 2023 01 24; 67(1):e0134622.

View in: PubMed
Lob SH, Estabrook MA, DeRyke CA, Alekseeva I, Siddiqui F, Young K, Motyl MR, Sahm DF. Activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa from patients in the Middle East and Africa - Study for Monitoring Antimicrobial Resistance Trends (SMART) 2017-2020. Int J Infect Dis. 2022 Dec; 125:250-257.

View in: PubMed
Karlowsky JA, Lob SH, DeRyke CA, Hilbert DW, Wong MT, Young K, Siddiqui F, Motyl MR, Sahm DF. In Vitro Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 2020. Antimicrob Agents Chemother. 2022 05 17; 66(5):e0018922.

View in: PubMed
Karlowsky JA, Lob SH, Khan A, Chen WT, Woo PCY, Seto WH, Ip M, Leung S, Wong QW, Chau RWY, DeRyke CA, Young K, Motyl MR, Sahm DF. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019. J Med Microbiol. 2022 Apr; 71(4).

View in: PubMed
Karlowsky JA, Kazmierczak KM, Valente MLNF, Luengas EL, Baudrit M, Quintana A, Irani P, Stone GG, Sahm DF. In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017-2019. Braz J Infect Dis. 2021 Nov-Dec; 25(6):101647.

View in: PubMed
Karlowsky JA, Lob SH, Kazmierczak KM, Young K, Motyl MR, Sahm DF. In-vitro activity of imipenem/relebactam and key ?-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients - SMART Surveillance United States 2015-2017. Int J Antimicrob Agents. 2020 Jan; 55(1):105841.

View in: PubMed
Lob SH, Hoban DJ, Young K, Motyl MR, Sahm DF. Activity of ceftolozane-tazobactam and comparators against Pseudomonas aeruginosa from patients in different risk strata - SMART United States 2016-2017. J Glob Antimicrob Resist. 2020 03; 20:209-213.

View in: PubMed
Karlowsky JA, Kazmierczak KM, Bouchillon SK, de Jonge BLM, Stone GG, Sahm DF. In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015. Antimicrob Agents Chemother. 2019 04; 63(4).

View in: PubMed
Kazmierczak KM, Bradford PA, Stone GG, de Jonge BLM, Sahm DF. In Vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015. Antimicrob Agents Chemother. 2018 12; 62(12).

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement